[go: up one dir, main page]

BRPI0915064A2 - derivados de qunoxalinadiona - Google Patents

derivados de qunoxalinadiona

Info

Publication number
BRPI0915064A2
BRPI0915064A2 BRPI0915064A BRPI0915064A BRPI0915064A2 BR PI0915064 A2 BRPI0915064 A2 BR PI0915064A2 BR PI0915064 A BRPI0915064 A BR PI0915064A BR PI0915064 A BRPI0915064 A BR PI0915064A BR PI0915064 A2 BRPI0915064 A2 BR PI0915064A2
Authority
BR
Brazil
Prior art keywords
qunoxalinadione
derivatives
qunoxalinadione derivatives
Prior art date
Application number
BRPI0915064A
Other languages
English (en)
Inventor
Daniel Cravo
Franck Leprife
Sophie Hallakou-Bozec
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0915064A2 publication Critical patent/BRPI0915064A2/pt
Publication of BRPI0915064B1 publication Critical patent/BRPI0915064B1/pt
Publication of BRPI0915064B8 publication Critical patent/BRPI0915064B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0915064A 2008-06-16 2009-05-19 derivados de quinoxalinadiona, seus usos, e medicamentos BRPI0915064B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290564.7 2008-06-16
EP08290564 2008-06-16
PCT/EP2009/003538 WO2009152909A1 (en) 2008-06-16 2009-05-19 Quinoxalinedione derivatives

Publications (3)

Publication Number Publication Date
BRPI0915064A2 true BRPI0915064A2 (pt) 2015-10-27
BRPI0915064B1 BRPI0915064B1 (pt) 2019-10-08
BRPI0915064B8 BRPI0915064B8 (pt) 2021-05-25

Family

ID=40823394

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915064A BRPI0915064B8 (pt) 2008-06-16 2009-05-19 derivados de quinoxalinadiona, seus usos, e medicamentos

Country Status (24)

Country Link
US (2) US8329698B2 (pt)
EP (1) EP2285786B1 (pt)
JP (1) JP5596676B2 (pt)
KR (1) KR101641391B1 (pt)
CN (1) CN102066342B (pt)
AR (1) AR072148A1 (pt)
AU (1) AU2009259754B2 (pt)
BR (1) BRPI0915064B8 (pt)
CA (1) CA2728018C (pt)
CO (1) CO6321252A2 (pt)
CY (1) CY1114737T1 (pt)
DK (1) DK2285786T3 (pt)
EA (1) EA020236B1 (pt)
EC (1) ECSP11010760A (pt)
ES (1) ES2436195T3 (pt)
HR (1) HRP20131069T1 (pt)
IL (1) IL209421A (pt)
MX (1) MX2010013577A (pt)
MY (1) MY155695A (pt)
NZ (1) NZ590503A (pt)
PL (1) PL2285786T3 (pt)
PT (1) PT2285786E (pt)
SI (1) SI2285786T1 (pt)
WO (1) WO2009152909A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
DK3424920T3 (da) 2013-10-17 2020-06-08 Vertex Pharma Co-krystaller af (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinolin-4-carboxamid og deuterede derivater deraf som dna-pk-inhibitorer
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法
EP3941496A4 (en) * 2019-03-18 2022-11-23 University of Washington METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP4249489A4 (en) * 2020-11-26 2023-10-18 Lg Chem, Ltd. HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CA3238252A1 (en) 2021-11-19 2023-05-25 Amit Choudhary Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
EP0963372A1 (en) 1997-02-18 1999-12-15 American Home Products Corporation 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
AU2002314101A1 (en) 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh &Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
MXPA06007715A (es) 2004-01-06 2007-01-26 Johnson & Johnson Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad.
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
EP2018167A4 (en) * 2006-05-15 2010-07-14 Irm Llc COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ECSP11010760A (es) 2011-02-28
HK1157784A1 (en) 2012-07-06
US8674097B2 (en) 2014-03-18
EA201100007A1 (ru) 2011-08-30
BRPI0915064B8 (pt) 2021-05-25
KR20110017455A (ko) 2011-02-21
IL209421A (en) 2015-06-30
CO6321252A2 (es) 2011-09-20
PT2285786E (pt) 2014-01-07
MX2010013577A (es) 2010-12-21
US20120322806A1 (en) 2012-12-20
EA020236B1 (ru) 2014-09-30
US8329698B2 (en) 2012-12-11
EP2285786B1 (en) 2013-10-09
IL209421A0 (en) 2011-01-31
EP2285786A1 (en) 2011-02-23
CA2728018A1 (en) 2009-12-23
BRPI0915064B1 (pt) 2019-10-08
US20110130404A1 (en) 2011-06-02
CA2728018C (en) 2016-10-11
ES2436195T3 (es) 2013-12-27
CN102066342A (zh) 2011-05-18
AR072148A1 (es) 2010-08-11
SI2285786T1 (sl) 2014-02-28
KR101641391B1 (ko) 2016-07-20
NZ590503A (en) 2012-08-31
AU2009259754A1 (en) 2009-12-23
JP2011524384A (ja) 2011-09-01
JP5596676B2 (ja) 2014-09-24
CY1114737T1 (el) 2016-12-14
AU2009259754B2 (en) 2014-10-02
PL2285786T3 (pl) 2014-01-31
DK2285786T3 (da) 2013-11-04
MY155695A (en) 2015-11-13
WO2009152909A1 (en) 2009-12-23
HRP20131069T1 (hr) 2013-12-20
CN102066342B (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0915064A2 (pt) derivados de qunoxalinadiona
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINDERIVAT
EP2380877A4 (en) PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0921327A2 (pt) Combinação de herbicida-protetor
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0812518A2 (pt) Derivados de indazolamida
EP2336132A4 (en) MORPHOLINPURINDERIVAT
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0913234A2 (pt) derivados de tiazolilpiperidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2828 DE 18-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.